Sirolimus

  • PDF / 169,681 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 47 Downloads / 137 Views

DOWNLOAD

REPORT


1

S

Coronary artery aneurysm: case report In a single-center, retrospective, observational study of 11982 patients, conducted between August 2006 and August 2018, a patient [age and sex not stated] was described, who developed coronary artery aneurysm (CAA) following implantation of a sirolimus eluting stent. The patient underwent implantation of a sirolimus eluting stent [Orsiro; indication and dosage not stated]. The patient received various medications prior to the procedure, and was maintained on unspecified dual-antiplatelet medications post implantation, scheduled for at-least 6 months. Periprocedurally, the patient received heparin [unfractionated heparin] in order to maintain an activated clotting time of >250s. During a follow-up angiography, the patient was detected with sirolimus-related CAA [time to reaction onset and outcome not stated]. Author comment: "The inflammatory response to the drugs increased eosinophilic or heterophilic infiltration into the vessel, as well as the occurrence of local toxic effects. These mechanisms induce weakening and disruption of the arterial wall, provoking arterial wall expansion and aneurysmal change." Hong SJ, et al. Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation. Yonsei Medical Journal 60: 824-831, No. 9, Sep 2019. Available from: URL: http://doi.org/10.3349/ymj.2019.60.9.824 - South 803431534 Korea

0114-9954/19/1777-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 2 Nov 2019 No. 1777